To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted (N=28) vs actual body weight (N=50).
To compare the incidence of hospitalization for upper GI tract bleeding, researchers used US Medicare beneficiary files to identify a cohort of patients that were ≥30 years old who initiated oral anticoagulation therapy with apixaban, dabigatran, rivaroxaban, or warfarin, with or without PPI cotherapy.
For this review, researchers performed an extensive literature search for studies and cases where an adverse drug reaction occurred likely due to an interaction between an herbal and a prescribed medicine.
The Food and Drug Administration (FDA) has approved updated labeling for several hepatitis C virus (HCV) infection treatments.
The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.
The ROCKET-AF study provided the primary data to support the 2011 approval of Xarelto.
Treatment recommendations were made taking into account the possibility of reduced glomerular filtration rate and drug-drug interactions.
Clinicians should be aware of this possible adverse event and monitor patients receiving concomitant drugs that may prolong the QT interval.
Patients may not be fully aware of the foods and drugs that can interfere with warfarin treatment and cause serious side effects